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Summary 
Previously, we have shown that a multicopy family of related but unique  genes encodes the 
major surface glycoprotein (MSG) of Pneumocystis  carinii. To examine whether different mem- 
bers of this gene family are expressed by P. carinii, antisera were prepared against peptides whose 
sequences were determined from the deduced amino acid sequences of variants of rat-derived 
MSG. Immunohistochemical staining of serial sections of rat lungs of infected animals showed 
that at least three variants of MSG were expressed in an individual lobe, that there was a focal 
expression of these variants within the lung,  and that the relative numbers of these foci were 
different. Indirect immunofluorescent staining of purified P. carinii organisms using these anti- 
sera revealed that at least three variants of MSG were present in organisms isolated from an in- 
dividual rat and that both cysts and trophozoites reacted with each antiserum. A substantial dif- 
ference  in  the  fraction  of organisms reacting with  a  specific antipeptide  antiserum was seen 
when comparing organisms isolated from rats raised in a single  colony over a period of two 
years as well as organisms isolated at one time point from rats raised in different colonies. This 
demonstration of antigenic variation in P.  carinii supports the hypothesis that P.  carinii utilizes 
such variation for evading host defense mechanisms. 
p neumocystis  carinii is a major opportunistic pathogen of 
patients with HIV infection (1,  2). Although P.  carinii 
cannot be reliably cultured in vitro, studies using organisms 
obtained from immunosuppressed animals have led to im- 
portant advances in our understanding of the basic biology 
of this pathogen, including strong evidence to support its re- 
classification  from a protozoan to a member of the fungi (3). 
While important differences exist in P.  carinii organisms 
isolated from different hosts, all possess an abundant, highly 
immunogenic,  major  surface  glycoprotein  (MSG),  also 
called  gpA  (4-6).  MSG  shows  a  size  on  reducing  SDS- 
PAGE of between 95 and 120 kD (7).  cDNA or genomic 
clones encoding MSG derived from rats,  humans, and fer- 
rets have been isolated and sequenced (8-10). These studies 
indicate that MSGs from each host are encoded by a unique 
family of related but distinct genes, which,  for rat-derived 
P.  carinii, are present as tandem arrays within  the genome 
(11).  Recently,  we and others  have shown that there  ap- 
pears to be a single  or very limited number of expression 
sites for the MSG genes (12,  13). 
MSG appears to be strongly involved in P. carinii attach- 
ment mechanisms (14-17)  and to be a target for host im- 
mune  response  (18,  19)  and  thus  is  a  good  candidate  for 
vaccine  development.  Recently  it  has  been  shown  that 
cDNAs produced from mRNA obtained from the lungs of 
a  single  immunosuppressed infected rat  code for multiple 
variants of MSG (20),  supporting the concept that a single 
isolate of P. carinii can express different MSG variants. The 
potential ability of P. carinii to express different MSG vari- 
ants suggests that the organism is utilizing antigenic varia- 
tion as a means of evading host immune defenses, which may 
interfere with the efficacy of a vaccine. To examine this ques- 
tion more directly, we used epitope-specific antibodies to 
examine the expression of MSG variants in a single host. In 
this report, we demonstrate that multiple variants of MSG 
are expressed within one rat and that the expression pattern 
may change with time and with location.  In addition,  we 
present evidence that within a single lobe this variation is 
focal, suggesting a clonal expansion of P.  carinii organisms 
within the lung. 
Materials and Methods 
Preparation of Organisms.  P.  caFinii organisms  were  obtained 
from the  lungs of male  Sprague-Dawley rats as previously  de- 
scribed  (21). National Institutes of Health (NIH) rats were pur- 
chased from the National Cancer Institute Frederick Animal Pro- 
duction Unit and housed  at one facility at the NIH. Biocon rats 
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in Kockville, MD. Cages were not isolated from each other.  An- 
imals were killed when they appeared  ill, as evidenced by ruffled 
hair, weight loss, and rapid respiration.  Lungs were aseptically re- 
moved and used only if they were found to be heavily infected 
with P. carinii and free of significant bacterial or other fungal in- 
fection. For histopathologic  studies, lungs were preserved in His- 
tochoice and embedded in paraffin. For studies using intact P. car- 
inii,  organisms were partially purified by Ficoll-Hypaque density 
gradient centrifugation, washed  in PBS,  pelleted,  and stored  at 
-70~ 
Indirect Immunofluorescence.  Partially  purified P.  carinii organ- 
isms were thawed on ice, resuspended twice in 1 ml of 0.1 M gly- 
cine, pH 2.5, to remove bound immunoglobulins,  resuspended in 
3 ml of PBS, filtered through a nylon 10-~m filter (Micron Sepa- 
rations  Inc.,  Westborough,  MA),  and  adjusted  with  PBS  to 
ODr0 0  =  1.0. 20 ~1 was smeared on a plain glass slide, allowed to 
air dry, fixed in ice-cold acetone for 5 min, and stored at 4~  un- 
til staining. 
For immunofluorescent staining,  slides were washed  once in 
water,  layered with 0.25 ml of 10% lamb serum (Life Technolo- 
gies, Grand Island, NY) for 1 h, and then washed twice with pH 
7.2 Tris-buffered saline (TBS). Anti-peptide antisera were diluted 
1:50 in 10% lamb serum, and 0.25 ml was layered onto the slides 
for 1 h and then washed twice in TBS. The slides were next lay- 
ered for 30 min with 0.25 ml offluorescein-conjugated  goat anti- 
rabbit antibodies (Organon Teknika, West Chester,  PA) diluted 
1:50 in 10% lamb serum, then washed twice in TBS, after which 
they were  coated  with 0.25  ml of rhodamine-conjugated con- 
canavalin A  (Sigma Chemical Co., St. Louis, MO), 0.25  p~g/ml 
for 30 min, and washed twice in TBS.  Concanavalin A has been 
shown to bind to both trophozoites and cyst forms  of P.  carinii 
(22). Finally, slides were mounted under VectaShield (Vector Lab- 
oratories, Inc., Burlingame, CA). 
Preparation ofAnti-peptide  Antisera.  Antisera GP3/PC3 and PC5 
were produced by Research Genetics (Huntsville,  AL) in rabbits 
against  keyhole limpet hemocyanin-conjugated peptides  as  de- 
scribed  (8). The peptide used  for the production of GP3/PC3 
corresponds to amino acid residues 446-460 of GP3 and 453-467 
of PC3 (ELIKGNLGLVRFYSDP);  PC5 corresponds  to residues 
365-379 of the homologous region of PC5  (ELKGKLGHVR- 
FYSDP), based on the numbering  as reported in reference  8. An- 
tiserum MGP3 was raised by Chiron Mimotopes (Clayton, Aus- 
tralia) in 15  BALB/c  mice immunized with peptide covalently 
coupled to diphtheria toxoid via a cysteine residue  added to the 
NH  2 terminus of the peptide TPGGETGASGGTPGT (residues 
848-853 of GP3 [8]). Mice were injected with 20 btg ofpeptide 
per  injection, with  Freund's complete  adjuvant on  day  1  and 
Freund's incomplete adjuvant on day  14. Ammals were bled on 
day 58, and sera from all animals were pooled. 
Anti-P. carinii mAb.  Mouse mAb 4D7  was prepared  against 
rat-derived P. carinii and characterized  as described  (23). 
Immunohistochemistry.  Lungs were fixed  via tracheal  infusion 
and immersion in Histochoice fixative (Amresco, Inc., Solon, OH) 
and embedded in paraffin. Tissue sections were processed with a 
streptavidin-alkaline phosphatase  (SAAP) detection system  and 
evaluated for immunoreactivity  with rabbit antisera GP3/PC3 or 
PC5 diluted 1:50 in PBS with Tween 20 (PBST), or a 1:50 dilu- 
tion in PBST of tissue culture supernatant of mouse anti-pneu- 
mocystis mAb 4D7. In brief, serial 5-btm tissue sections were col- 
lected  on positively  charged  glass slides (SuperfrostPlus;  Fisher 
Scientific,  Pittsburgh,  PA),  deparaffinized,  rehydrated,  and then 
blocked in 2% normal goat or horse serum in PBST for 20 n'fin at 
room temperature in a humidified chamber. After the blocking 
serum was drained, sections were incubated with primary antibod- 
ies diluted in PBST for 1 h under the same conditions. Sections 
were washed with PBST and then incubated for 30 min with bi- 
otinylated goat anti-rabbit or horse anti-mouse IgG antibody (Vec- 
tor  Laboratories),  diluted  1:200  in PBST.  After  another PBST 
wash, sections were incubated for 30 rain with streptavidin-alka- 
line phosphatase  (GIBCO BRL, Gaithersburg,  MD), diluted 1:50 
in PBST. The chromogenic substrate for alkaline phosphatase was 
HistoMark  Red (Kirkegaard and Perry, Gaithersburg, MD). Color 
development progressed for 50 rain in the dark, and then sections 
were washed  in distilled water and counterstained with Mayer's 
hematoxylin (Poly Scientific, Bay Shore,  NY). Negative controls 
included replacing the primary antisera with appropriate  preim- 
mune or nonimmune sera and applying the primary antisera to 
uninfected rat lung tissue. 
Results  and Discussion 
To determine whether different MSG variants were ex- 
pressed in a single lung, and whether there was a  discrete 
pattern to the  expression of MSG variants, we performed 
immunohistochemistry on  serial  sections  of a  P.  carinii- 
infected rat  lung,  using mouse mAb 4D7  to  visualize all 
P. carinii  (Fig.  1).  When  sequential  serial  sections  were 
probed with the polyclonal anti-peptide antisera anti-GP3/ 
PC3 or anti-PC5, distinct differences in the immunostain- 
ing pattern were observed (Fig. 2). There are clusters of or- 
ganisms that stain preferentially with either anti-GP3/PC3 
or with anti-PC5. Since most organisms that react with one 
of these anti-peptide antisera appear as tightly clustered foci, 
they seem likely to have arisen through the clonal prolifer- 
ation of P.  carinii  that express either the  GP3/PC3 variant 
or the PC5 variant. In addition, a comparison between the 
relative numbers of foci stained with the anti-peptide anti- 
sera and the total number of organisms as visuahzed by 4D7 
shows that whereas both GP3/PC3 and PC5  epitopes are 
found frequently in this population, they by no means ac- 
count for all the MSG variants that are found in the lung of 
a single infected rat. These findings are consistent with a re- 
cent report  (20)  in which the simultaneous presence of at 
least seven distinct mRNA species encoding MSG was dem- 
onstrated in a single rat lung. 
Whereas the majority of clusters stain with only one of 
the anti-peptide antisera, there are clearly groups of organ- 
isms that stain with both.  These dual-staining clusters are 
found mostly in bronchioles or in alveoli continuous with 
bronchioles and may represent organisms being cleared from 
deeper  alveoh.  Alternatively, they  may  represent  variants 
that contain epitopes common to both peptides, since there 
is  an overlap  in the  sequences used to  generate the  anti- 
peptide antisera. 
To determine whether any variation in MSG expression 
occurred with respect to  either time or location, we per- 
formed indirect immunofluorescence assays (IFAs) on puri- 
fied P.  carinii  organisms. Fig. 3  shows  the results obtained 
when probing these organisms with the anti-peptide anti- 
sera.  Since P. carinii binds concanavalin A (22), organisms are 
seen as red when visualized with concanavalin A-rhodamine 
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tected by methenamine silver. (A) Methenamine-silver  staining ofa 5-1~m 
section of Histochoice-fixed, paraffin-embedded tissue. P. ca~inii cysts ap- 
pear brown. (B) Immunohistochemical staining of the same section of rat 
lung. P, carinii appear as deep-red clusters. Magnification: 400. 
alone. Yellow fluorescence is due to  a  combination of the 
red from concanavalin A-rhodamine, which reacts with all 
organisms, and the green fluorescence from the binding of 
specific  rabbit  anti-peptide  antisera  as  visualized by  goat 
anti-rabbit  FITC.  IFA  of organisms  obtained  from  the 
lungs of a  rat housed in the  NIH  colony through January 
1990  revealed  that  the  majority  of organisms  expressed 
epitopes that were  recognized by either anti-PC5  or anti- 
GP3/PC3  (Fig.  3,  bottom  left).  Both  cyst  and  trophozoite 
forms were recognized by each antibody. No  specific im- 
munofluorescence  was  seen  when  applying  preimmune 
sera (not shown).  By January  1993,  there was a  substantial 
decrease in the fraction of organisms that reacted with these 
two  antisera  (Fig. 3,  bottom  row,  left  and  center).  Most  dra- 
matic was a decline between 1990 and 1993 in the fraction 
of organisms isolated from NIH-housed rats that were re- 
active with anti-PC5  (top  row,  left  versus  center).  Fig. 3  also 
shows  that  organisms obtained at the  same  time from rats 
housed at a commercial facility (Biocon) contained a much 
higher fraction that were  IFA-positive with anti-PC5  plus 
anti-GP3/PC3  (bottom  row,  center and  right).  Much of this is 
apparently due to the higher levels ofimmunofluorescence 
obtained with  anti-PC5  against the Biocon organisms  (top 
Figure 2.  Focal expression of MSG variants in 5-1.~m serial sections of 
P.  carinii-infected  rat lung. Immunohistochemistry was performed using 
as primary antibodies either anti-peptide antisera PC5  (top) or GP3/PC3 
(middle), or mouse mAb 4D7 (bottom). The staining pattern is different for 
the  two  epitope-specific antibodies; all areas of reactivity correspond, 
however, to P. carinii organisms  as identified by antibody 4D7. Magnifica- 
tion: 400. 
row,  center and  right).  The results shown in Fig. 3  were ob- 
tained  for  individual  infected  rats  killed  at  the  indicated 
times.  Similar results were  obtained at  each  time  for four 
other rats killed at the same stage of infection within a 3-wk 
period (not shown).  Problems of clumping of the P.  carinii 
organisms (especially trophozoites) (24) prevented quantifi- 
cation of these findings. 
Since anti-GP3/PC3  recognizes an epitope common  to 
both GP3 and PC3, we utilized a second anti-peptide anti- 
serum,  raised in mice and designated as anti-MGP3 to de- 
1231  Angus et al.  Brief  Definitive Report Figure 3.  Binding of specific anti-peptide  antisera  raised in rabbits  to three preparations of rat-derived  P. carinii organisms.  Double-exposure  photogra- 
phy yields a red fluorescence  for organisms  that react with concanavalin  A-rhodamine only and yellow fluorescence  for organisms  that react with both 
the concanavalin  A-rhodamine and the green goat anti-rabbit FITC. The year in which the specimens were obtained and the source of the rats are 
shown across the top, while the anti-peptide  antiserum  used is shown on the left. Magnification:  630. 
termine which variant is expressed. Anti-MGP3 is directed 
to a region of GP3 (residues 843-857) that is more COOH- 
terminal than that used to produce anti-GP3/PC3. Fig. 4 
shows  the  immunofluorescent pattern  obtained with  this 
antiserum. The red fluorescence is from organisms that re- 
act with only anti-GP3/PC3, whereas a green fluorescence 
would be seen for those that react with only anti-MGP3, 
and a yellow fluorescence for those  that react with both. 
Although many organisms react with anti-GP3/PC3, only 
a small fraction of the organisms are immunoreactive  to both, 
indicating that only a minority of expressed MSGs possess 
GP3-1ike epitopes at both positions. No  P.  carinii  reacted 
with only anti-MGP3. Since the  deduced amino acid se- 
quence in this region of PC3 is unknown, the correspond- 
ing epitope in PC3  cannot be determined, but is presum- 
ably different  from  that  of GP3,  since  not  all  organisms 
reactive with anti-GP3/PC3 are reactive with anti-MGP3. 
There appear then to be at least four variants of MSG ex- 
pressed  in  these  preparations:  PC5-1ike,  PC3-1ike,  GP3- 
like,  and  at  least  one  other  variant that  reacted  with  no 
epitope-specific antibody. 
On the basis of these data, it is not possible to definitively 
conclude whether there  is  a variation in the levels of ex- 
Figure 4.  Expression  of GP3-specific epitopes in rat-derived P. carinii. 
Double-exposure photography yields a red fluorescence for organisms 
that react with anti-GP3/PC3 only and yellow fluorescence  for organisms 
that react both with anti-MGP3 detected by goat anti-mouse FITC and 
with anti-GP3/PC3 detected by goat anti-rabbit rhodamine. No organ- 
isms reacted only with anti-MGP3. Magnification:  630. 
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isms,  although it appears that the preponderance of organ- 
isms  are  either  negative  by  IFA or show  fluorescence  of 
similar  strong intensity.  It is also unclear whether both of 
these  epitopes  can be expressed simultaneously in an indi- 
vidual cyst or trophozoite.  It is clear,  however, that a shift 
in the pattern of epitope expression can occur among ani- 
mals  in  a  given  colony.  Since  it  has  been  established  that 
different strains of P. carinii can infect rats in a single colony 
(25, 26), one explanation for this observed variation is that 
the  colony harbored  different  strains,  each  expressing  dif- 
ferent epitopes that have intrinsically different growth rates, 
and  that  this  led  to  a  shift  in  the  expression  pattern  over 
time.  Thus by 1993,  the  dominant strain in the NIH col- 
ony was  one  that  expressed  neither  GP3/PC3  nor  GP3, 
but a third variant. Another, more interesting, possibility is 
that P. carinii  is varying the expression of MSG to evade host 
defense mechanisms. The best-characterized example of this 
type of antigenic variation is that found in the variable sur- 
face glycoprotein of  African trypanosomes, where hundreds 
of variants can be expressed as an evasion strategy (27). 
Since these studies were performed on rats that were im- 
munosuppressed by steroid administration,  there are inher- 
ent limitations.  These include time of onset of the P.  carinii 
pneumonia,  the  severity  and  duration  of the  infection, 
source of  latent or transmitted P. carinii,  and the presence of 
other pathogens. Further,  if P.  carinii has developed a strat- 
egy of antigenic variation, it presumably was developed to 
evade  immune  responses  in  an  immunologically  normal 
host,  not  an  irmnunosuppressed  host.  In  the  former,  the 
expression of MSG variants may be more ordered, while in 
the  latter,  the  need  for  antigenic  variation  may  be  lost, 
allowing multiple MSGs to be expressed at one time. Nev- 
ertheless,  this  work has  clearly shown  that  there  is  tem- 
poral  and  geographic  variation  in  the  expression  of spe- 
cific  epitopes  found  in  MSG,  and  that  in  an  individual 
animal, the expression of these epitopes is presented in a fo- 
cal fashion. 
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